Moberg Pharma Q3’22: Steadily moving towards commercialization - Redeye

Redeye’s comments on the Q3 report that was published earlier this morning. There were no sales, as expected. We see that Moberg Pharma is very much on schedule and we do not, at this point, see any significant obstacles on the horizon. We do not change our fair value range and Base case value of SEK 8 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/861801/moberg-pharma-q322-steadily-moving-towards-commercialization?utm_source=finwire&utm_medium=RSS